{"id":"https://openalex.org/W4233874866","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.3089","title":"Results from Phase I study of PX-12, a thioredoxin inhibitor in patients with advanced solid malignancies","display_name":"Results from Phase I study of PX-12, a thioredoxin inhibitor in patients with advanced solid malignancies","publication_year":2004,"publication_date":"2004-07-15","ids":{"openalex":"https://openalex.org/W4233874866","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.3089"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2004.22.14_suppl.3089","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.3089","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.3089","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088643712","display_name":"L. Kirkpatrick","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. Kirkpatrick","raw_affiliation_strings":["ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001412750","display_name":"T. Dragovich","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T. Dragovich","raw_affiliation_strings":["ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113733729","display_name":"Ramesh K. Ramanathan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Ramanathan","raw_affiliation_strings":["ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031954705","display_name":"E. Sharlow","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. Sharlow","raw_affiliation_strings":["ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":null,"display_name":"S. Chow","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Chow","raw_affiliation_strings":["ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111769492","display_name":"Daphne D. Williams","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Williams","raw_affiliation_strings":["ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001427470","display_name":"R. Himler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Himler","raw_affiliation_strings":["ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037149138","display_name":"A. Baker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Baker","raw_affiliation_strings":["ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113786887","display_name":"Merrill J. Egorin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Egorin","raw_affiliation_strings":["ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProlX Pharmaceuticals, Tucson, AZ; Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210128526"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"22","issue":"14_suppl","first_page":"3089","last_page":"3089"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11884","display_name":"Redox biology and oxidative stress","score":0.9872999787330627,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11884","display_name":"Redox biology and oxidative stress","score":0.9872999787330627,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12356","display_name":"Bioactive Compounds and Antitumor Agents","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/px-12","display_name":"PX-12","score":0.8840000033378601},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8379999995231628},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5289999842643738},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8059999942779541},{"id":"https://openalex.org/keywords/hypoxia","display_name":"hypoxia","score":0.6669999957084656},{"id":"https://openalex.org/keywords/pneumonitis","display_name":"pneumonitis","score":0.9729999899864197},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.6320000290870667},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.6150000095367432},{"id":"https://openalex.org/keywords/thioredoxin-1","display_name":"thioredoxin-1","score":0.777999997138977},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.8920000195503235},{"id":"https://openalex.org/keywords/hif-1alpha","display_name":"HIF-1\u03b1","score":0.906000018119812},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.621999979019165},{"id":"https://openalex.org/keywords/drug-metabolites","display_name":"drug metabolites","score":0.492000013589859},{"id":"https://openalex.org/keywords/infusion-time","display_name":"infusion duration","score":0.44699999690055847},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.6589999794960022},{"id":"https://openalex.org/keywords/gastric-cancer","display_name":"gastric cancer","score":0.8859999775886536},{"id":"https://openalex.org/keywords/lung-cancer","display_name":"lung cancer","score":0.9819999933242798},{"id":"https://openalex.org/keywords/appendiceal-carcinoma","display_name":"appendiceal carcinoma","score":0.875}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9177124500274658},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7245907783508301},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5980192422866821},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5781348943710327},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5068836808204651},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.4952980577945709},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4791949689388275},{"id":"https://openalex.org/C2779524853","wikidata":"https://www.wikidata.org/wiki/Q1284347","display_name":"Pneumonitis","level":3,"score":0.4693297743797302},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.44871997833251953},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4138838052749634},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.40810465812683105},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35625219345092773},{"id":"https://openalex.org/C2777714996","wikidata":"https://www.wikidata.org/wiki/Q7886","display_name":"Lung","level":2,"score":0.22717133164405823},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2004.22.14_suppl.3089","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.3089","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.3089","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"doi:10.1200/jco.2004.22.90140.3089","doi":"https://doi.org/10.1200/jco.2004.22.90140.3089","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.90140.3089","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2265836774","https://openalex.org/W2128650300","https://openalex.org/W2077245360","https://openalex.org/W4233569386","https://openalex.org/W2013933294","https://openalex.org/W1009961453","https://openalex.org/W2056660135","https://openalex.org/W1970438992","https://openalex.org/W2093156072","https://openalex.org/W744938011"],"abstract_inverted_index":{"3089":[0],"Background:":[1],"Thioredoxin-1":[2],"(Trx-1)":[3],"is":[4,344],"a":[5,28,79,103,116,153,205,225,320,335],"cellular":[6],"redox":[7],"protein":[8],"with":[9,67,130,149],"anti-apoptotic":[10],"and":[11,24,37,39,59,115,156,178,228,306,332],"angiogenic":[12],"properties.":[13],"High":[14],"levels":[15,223],"of":[16,31,48,61,105,185,214,235,239,251,264,277,287,297],"Trx-1":[17,222,253,260,284],"have":[18],"been":[19],"detected":[20],"in":[21,43,99,211,224,249],"colorectal,":[22],"gastric":[23],"lung":[25],"cancers.":[26],"PX-12,":[27],"small-molecule":[29],"inhibitor":[30],"Trx-1,":[32],"stimulates":[33],"apoptosis,":[34],"down-regulates":[35],"HIF-1\u03b1":[36],"VEGF":[38,291],"inhibits":[40],"tumor":[41],"growth":[42],"animal":[44],"models.":[45],"The":[46,256,275],"purpose":[47],"this":[49,229,288],"Phase":[50],"1":[51,244],"trial":[52,339],"was":[53,96,134,197,209,230,267,292,314,326],"to":[54,72,102,175,192,199,245,269,282,300],"determine":[55],"optimal":[56],"dosing,":[57],"safety":[58],"tolerability":[60],"PX-12.":[62],"Methods:":[63],"38":[64,215],"patients":[65,100,168,180],"(pts)":[66],"advanced":[68],"solid":[69],"tumors":[70],"refractory":[71],"standard":[73],"therapy,":[74,204],"were":[75,303],"administered":[76],"PX-12":[77,95,196,219,278,298],"as":[78,316,319],"1-hr":[80],"or":[81,131,359,362],"3-hr":[82,321],"infusion":[83,241,343],"on":[84,158,182,195,202,272,329],"d":[85],"1\u20135,":[86],"q":[87],"3":[88,188,246],"wks,":[89],"starting":[90],"at":[91],"9":[92,176],"mg/m2.":[93,107],"Results:":[94],"well":[97,304],"tolerated":[98,305],"up":[101,299],"dose":[104,313],"226":[106,138,301],"Common":[108],"grade":[109],"1/2":[110],"AE's":[111],"included":[112],"cough,":[113],"fever,":[114],"garlic":[117],"odor/irritation":[118],"caused":[119],"by":[120,347],"expired":[121],"drug":[122],"metabolite.":[123],"At":[124],"doses":[125],"\u2265226":[126],"mg/m2":[127,139,302,318],"reversible":[128],"hypoxia":[129],"without":[132],"pneumonitis":[133],"observed.":[135,327],"Dosing":[136],"below":[137],"appears":[140],"safe":[141],"for":[142,160],"future":[143],"studies.":[144],"Tumor":[145],"Response:":[146],"One":[147],"patient":[148],"appendiceal":[150],"carcinoma":[151],"achieved":[152,169],"minor":[154],"response":[155],"remained":[157],"therapy":[159,186],"14":[161],"cycles":[162,184],"(9":[163],"-":[164],"36":[165],"mg/m2dose),":[166],"6":[167,174],"disease":[170],"stabilization":[171],"(SD)":[172],"lasting":[173],"cycles,":[177],"8":[179],"stayed":[181],"4\u20135":[183],"(SD\u2265":[187],"months).":[189],"When":[190],"time":[191,242],"progression":[193],"(TTP)":[194],"compared":[198],"that":[200],"observed":[201],"prior":[203],"significant":[206],"TTP":[207],"prolongation":[208],"found":[210],"7":[212],"out":[213],"pts.":[216],"Pharmacodynamics":[217],"(PD):":[218],"lowered":[220,268],"circulating":[221],"dose-dependent":[226],"manner":[227],"maintained":[231],"during":[232],"treatment":[233],"cycle":[234],"21":[236],"d.":[237],"Prolongation":[238],"the":[240,252,283,310,330,354],"from":[243,353],"hrs":[247],"resulted":[248],"augmentation":[250],"lowering":[254,285],"effect.":[255],"average":[257],"pre-treatment":[258],"plasma":[259],"level":[261],"(38":[262],"pts)":[263],"94":[265],"ng/ml":[266,271],"54":[270],"day":[273],"21.":[274],"pharmacokinetics":[276],"major":[279],"metabolite":[280],"corresponded":[281],"ability":[286],"drug.":[289],"Circulating":[290],"also":[293],"lowered.":[294],"Conclusions:":[295],"Doses":[296],"had":[307],"minimal":[308],"toxicity;":[309],"optimum":[311],"PD":[312,333],"identified":[315],"96":[317],"infusion.":[322],"Preliminary":[323],"antitumor":[324],"activity":[325],"Based":[328],"PK":[331],"data,":[334],"follow-up":[336],"phase":[337],"IB":[338],"using":[340],"prolonged":[341],"24-hr":[342],"planned.":[345],"Supported":[346],"ProlX":[348,373,375,377,379],"Pharmaceuticals":[349,374,376,378,380],"through":[350],"an":[351],"award":[352],"NCI.":[355],"Author":[356],"Disclosure":[357],"Employment":[358],"Leadership":[360],"Consultant":[361],"Advisory":[363],"Stock":[364],"Ownership":[365],"Honoraria":[366],"Research":[367],"Funding":[368],"Expert":[369],"Testimony":[370],"Other":[371],"Remuneration":[372],"Corporation":[381]},"counts_by_year":[{"year":2019,"cited_by_count":1}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2022-05-12T00:00:00"}